All In Biotech

Drug Trial Radar · NCT07422389

BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

Intermediate-Size Patient Population Use of BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
BRIM Biotechnology Inc.Industry
Sponsor type
Industry
Collaborators
University of Pennsylvania
First posted
Feb 20, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: * Use BRM421 two times a day for at least 12 weeks * Visit the clinic monthly for checkups and tests

Conditions

  • Limbal Stem Cell Deficiency (LSCD)

Interventions

  • BRM421 Ophthalmic Solution, 0.06%Drug

    Patients eligible to participate will receive 0.06% BRM421 Ophthalmic Solutions to be administered two times daily (BID, morning and bedtime) on the eligible eye(s). The administration will be at least 12 weeks. The investigator may continue the treatment beyond the 12 weeks based on clinical response. For patients scheduled for LSC transplant, treatment with BRM421 should start only after surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scheie Eye Institute

    Philadelphia, Pennsylvania · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.